XML 69 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
May 10, 2021
Oct. 10, 2020
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2020
Dec. 20, 2018
May 25, 2022
Revenue     $ 13,208,504   $ 14,846,925   $ 26,280,304 $ 26,466,001 $ 56,239,667   $ 55,406,337    
Foreign curreny translation             159,352   423,245        
Net income (loss)     (1,241,256) $ 203,347 (2,379,056) $ (2,173,903) (1,037,909) (4,552,959) $ (7,961,649) $ 820,786 $ 820,786    
Debt instrument conversion price                         $ 0.62152
Shares issued                 17,544,509 13,485,128 13,485,128    
Accrued interest     1,429,722       1,429,722   $ 1,019,889 $ 742,374 $ 742,374    
Grigorios Siokas Three [Member]                          
Foreign curreny translation                 20,623   27,114    
Additional proceeds from debt             426,612   275,306        
Outstanding principal balance     426,612       426,612   1,293,472 1,629,246 1,629,246    
Repayment of loans             449,643   133,552        
Net income (loss)             88,639            
Borrowing                 $ 2,040,635        
Debt instrument conversion price                 $ 6.00        
Convertible share description                 Mr. Siokas whereby the Company exchanged an aggregate total of $6,000,000 of debt into 1,000,000 shares of Common Stock at above market prices.        
Debt instrument converted amount                 $ 2,250,000        
Shares issued                 375,000        
Grigorios Siokas [Member]                          
Outstanding principal balance     418,760       418,760   $ 452,720 489,200 489,200    
Borrowing                       $ 1,718,400  
Maturity date                       Mar. 18, 2019  
Accrued interest     195,399       195,399   200,683 193,585 193,585    
Interest rate                       4.70%  
Litigation settlement $ 600,000                        
Plantiff attorney fees 120,000                        
Litigation cost $ 4,137                        
Dimitrios Goulielmos [Member]                          
Outstanding principal balance     10,678       10,678   11,544 12,475 12,475    
Gain incured             34,826            
DOC Pharma S.A. [Member]                          
Prepaid balance     4,120,335       4,120,335   3,263,241 3,468,564 3,468,564    
Accounts payable balance     511,143       511,143   565,756        
Net prepaid balance     3,609,192       3,609,192            
Accounts receivable balance     2,299,982       2,299,982   2,901,300 $ 3,468,653 3,468,653    
Payments to purchase products     624,627   1,091,118   1,328,435 1,413,924 3,084,805   5,983,809    
Revenue     34,132   $ 523,712   418,717 $ 796,917 978,321   2,843,260    
Foreign curreny translation                 $ 37,411   $ 122,279    
Agreement term                 5 years        
Pieces per product                 1,000 pieces        
Inventroy purchase                 $ 2,010,517        
Description of research and development                 Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($295,739) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025        
DOC Pharma S.A. [Member] | Outsourcing Agreement [Member]                          
Agreement term   5 years                      
Pieces per product   1,000                      
Inventroy purchase     $ 289,860       289,860            
Grigorios Siokas Four [Member]                          
Additional proceeds from debt             $ 100,000